The close association of obesity with an increased risk of metabolic diseases, such as insulin resistance, type 2 diabetes, and nonalcoholic fatty liver disease, is now well established. In this review, we aim first to describe the inflammatory process activated in response to overnutrition, especially in the liver and the adipose tissue. We then discuss the systemic effects of low-grade inflammation on the onset of insulin resistance. Particular attention is given to a series of very recent reports that identify not only processes but also molecules (lipids and metabolites) that interfere with the normal insulin signaling. Finally, special notes concerning the roles of peroxisome proliferatoractivated receptors in the various processes will be made.
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Keywords: insulin resistance; liver-adipose tissue cross-talk; metaflammation; PPARs; visceral white adipose tissue Obesity is a complex chronic disorder with a multifactorial etiology, involving genetics, hormones, diet, and life style. It is characterized by a massive increase in adipose tissue due to the imbalance between daily energy intake and energy expenditure. In the last 30 years, obesity has become a worldwide epidemic affecting both adult and children and turning into an extremely important public health problem [1] . Indeed, it is associated with many different (co)morbidities, such as cardiovascular diseases, type 2 diabetes (T2D), hypertension, certain cancers, and sleep-disordered breathing such as sleep apnea contributing to an increase risk of mortality as well as reduced life expectancy. Although carrying a large amount of fat is not necessarily harmful, two interlinked systemic disorders contribute to the high morbidity, that is, insulin resistance and inflammation, the latter being thought to play an important role in the pathogenesis of the former [2] . The link between these two processes is illustrated by the increased levels of several inflammatory cytokines in serum of T2D patients compared to healthy subjects. Up to 30% of obese patients are considered as 'metabolically healthy obese individuals' because of their normal fasting glucose, normotension, high insulin sensitivity, and inflammatory status [3, 4] . This concept was substantiated in many clinical studies, although it has been recently challenged by a study showing that insulin-sensitive and insulin-resistant obese have similar insulin-dependent transcriptional response in subcutaneous adipose tissue [5] .
Both the adipose tissue and the liver are primary targets of increased fluxes of fat upon obesity. In this review, we will first discuss the critical role of adipose tissue in metabolic homeostasis. We will mainly focus on how the altered circulating fatty acid levels affect adipose tissue homeostasis, modify the profile of adipokines and cytokines secreted by the adipocyte, and favor the recruitment of immune cells. These events are indeed considered as important contributors to the pathogenesis of the metabolic syndrome. The inflammatory responses of the liver will then be discussed. Indeed, the rise in human obesity has been recently correlated with an increased prevalence of nonalcoholic fatty liver disease (NAFLD) [6] . NAFLD is considered as the hepatic manifestation of the metabolic syndrome and is characterized by an excessive accumulation of triglycerides (TGs) in the hepatocytes, known as 'hepatosteatosis', in the absence of alcohol abuse or viral infection. Based on epidemiological studies, the percentage of obese subjects showing signs of NAFLD (75%) is increasing exponentially compared to lean subjects (16%), whereas it is close to 100% among the obese patients with T2D [7] . Importantly, we will emphasize how the signaling cross-talks between liver and adipose tissue relies both on inflammatory and metabolic signals. In the section Linking metabolism and inflammation, we will more specifically discuss the nature and actions of different actors that contribute to the insulin resistance in the context of inflammation. A final section will summarize the role that the transcription factor peroxisome proliferator-activated receptors (PPARs) plays in the onset of inflammation and insulin resistance.
Profound remodeling of the visceral white adipose tissue in overnutrition and obesity
In humans, adipose tissue is distributed over the entire body with many compartments that differ in terms of metabolic activity, sympathetic innervation, and contribution to local and systemic signaling. Although the brown adipose tissue (BAT) is orientated toward use of lipids, coupled to a thermogenic process, the white adipose tissue (WAT) is the main location for lipid storage, expanding in response to high fat or overnutrition (see Box 1) . The WAT is prone to develop inflammation upon obesity and thus is the focus of the present review.
Visceral WAT and subcutaneous WAT
When considering the impact on the development of metabolic disorders, two main types of WAT have been identified: the subcutaneous WAT (scWAT) which is located under the dermal compartment of the skin, and the visceral WAT (vWAT) further divided into the mesenteric WAT wrapped around the intestine, the retroperitoneal WAT surrounding the kidney, and the omental WAT positioned in the lower part of the abdominal cavity covering the stomach. This anatomic classification of the vWAT is not strictly reproduced in mice where omental fat is absent, and the tissue presenting the properties of visceral fat in mouse is the gonadal fat.
Visceral and subcutaneous adipose tissues have different behaviors, particularly highlighted in obesity and related metabolic disorders. These differences are of three types. Firstly, adipokine nature and secretion profile of vWAT and scWAT differ. For example, the expression and secretion of Interleukin 6 (IL6) and Plasminogen-Activator Inhibitor type 1 (PAI-1) are higher in the vWAT, whereas leptin and adiponectin are higher in subcutaneous WAT [8, 9] . Secondly, the adipokines produced by the scWAT are secreted into the systemic circulation, whereas those produced by vWAT are secreted into the portal system, thus having a more direct impact on hepatic metabolism. Thirdly, the rate of lipolysis and fatty acid mobilization [10] is also different, the visceral adipose tissue appearing to be more sensitive to lipolytic effects of catecholamines and less sensitive to the antilipolytic effects of insulin, that mobilizes fatty acids into the portal vein. Although these differences are possibly due to the vWAT-vs scWAT-specific environment, which includes the innervation and vasculature proper to each depot, recent reports suggested that physiological heterogeneity within the adipose tissues could also stem from different developmental programs, leading to cell-autonomous differences [11] [12] [13] .
These differences explain at least in part the major distinct response of each WAT depot upon obesity in human and in experimental models, including genetically induced obese mice, ob/ob and db/db, lacking the coding gene for leptin or for leptin receptor, respectively, as well as diet-induced obese mice.
In the rest of this chapter, we will thus discuss how the remodeling of the vWAT in overnutrition and obesity is a sequential process that starts with the development of mature hypertrophic adipocytes that have to face oxidative and endoplasmic reticulum (ER) stress. Their altered secretome initiates the inflammation process, with the recruitment of a large number of macrophages as well as the modification of the profile of pre-existing adipose tissue-resident macrophages (ATM). Finally, activated macrophages lead to the recruitment and activation of T lymphocytes, which altogether sustain the progression of obesity-induced inflammation. Recent knowledge concerning this process is discussed below. However, it must be reminded that the triggering stimuli as well as the exact temporal sequence of inflammatory cell infiltration and their cross-talk with stressed adipocytes is not completely clear, due to its intrinsic complexity and the difficulties in taking into account the various experimental contexts (e.g., animal model, type of diet, selected time points).
Cellular and tissular responses of the vWAT in obesity
White adipose tissue has the unique capacity to undergo dramatic remodeling in response to nutritional factors by increasing the size of individual cells (hypertrophy) and by recruiting new adipocytes from the resident pool of progenitors (hyperplasia). These processes, which aim to positively improve the lipid storage capacity of the body, are however accompanied, particularly in vWAT, by a reduction in tissue vascularization, leading to areas with lower oxygen availability and hypoxya [14, 15] . This alters in the vWAT some cellular and tissular responses and results in an undesirable infiltration and activation of immune and inflammatory cells, observed both in experimental models and in humans.
The first response of the adipose tissue to the high levels of circulating lipids is an hypertrophic growth of the pre-existing mature adipocytes as a result of the triglyceride accumulation in the unilocular lipid droplet. The hyperplasia process also starts quite rapidly since in mice adipogenesis and adipocyte precursor proliferation are already activated 3 days after the beginning of a high-fat diet feeding in vWAT depots, with the subsequent creation of a pool of precursors that will turn into mature adipocytes over a prolonged exposition to the diet (7 weeks) [16] . Notably, the hypertrophic process-rather than the hyperplasiaseems to be the most damaging for the cells and thus for the tissue.
At the cellular level, one of the consequences of the hypertrophic response is the decrease in insulin-dependent glucose uptake because of a dysregulation of cortical actin remodeling and the consequent impairment of insulin-dependent glucose transporter 4 (GLUT4) translocation to the plasma membrane [17] . Another alteration in hypertrophic adipocytes is the accumulation of radical oxygen species (ROS) [18] and dysfunction of the ER, a membranous network controlling Box 1. The adipose tissue properties and its diverse depots Heterogeneity of the adipose tissue (AT) Adipose tissue is a highly plastic tissue composed of preadipocytes, mature adipocytes, and stromal-vascular cells, coexisting with nerve terminals, blood vessels and lymph nodes, and immersed in a complex collagen matrix.
The two main properties of AT
• Capacity to store and to release lipids, depending on the energy demand of the organism.
• Secretion of bioactive peptides, called adipokines, that act both locally and systemically for the maintenance of energy homeostasis. Main adipokines are leptin, adiponectin, and resistin, which regulate feeding behavior and energy expenditure. Other cytokines can also be expressed by adipocytes. Both the storage function and the secretome are altered upon overnutrition.
The white, brown, and brite adipocytes The white adipocytes store lipids in one large lipid droplet surrounded by a thin layer of cytoplasm. The white adipose tissue (WAT) grows through increased cell size and increased cell number. The subcutaneous WAT (scWAT) and the visceral WAT (vWAT) have distinct properties (see the main text). The brown adipocytes accumulate lipids in several small lipid droplets and are characterized by a high number of densely packed mitochondria and expression of the uncoupling protein UCP1. The stored lipids are mainly used in nonshivering thermogenesis. The brown adipose tissues (BAT) are, in humans, mainly localized in the para-clavicular and spinal region [227] [228] [229] . The brite or 'brown-in-white [230] ' adipocytes correspond to inducible brown cells appearing in a predominantly white fat depot. The 'browning' process is induced by cold or beta-adrenergic stimuli and depends on the genetic background and on the location [231] . Raising the number and the activity of human brown cells can boost the whole-body energy expenditure, and is therefore the focus of enormous research efforts. White adipocytes derive from mesenchymal stem cells, whereas brown adipocytes derive from precursor cells in the embryonic mesoderm [232] . synthesis, maturation, and trafficking of secreted and membrane proteins. The accumulation of unfolded proteins in the ER lumen induces an adaptive response known as unfolded protein response (UPR) that is mediated by three major transducers: the PKR-like ER Kinase (PERK), the Inositol-Requiring Enzyme 1 (IRE1), and the Activating Transcription Factor 6 (ATF6). Along this line, chronic obesity is associated with ER stress in adipose tissue [19] and free fatty acids (FFA; also called nonesterified fatty acids) induce ROS generation as well as ER stress by activation of UPR signaling pathways in adipocytes [20] .
At the tissular levels, adipocyte hypertrophy is associated with a relative deficiency of vasculature that creates a local imbalance between oxygen supply and consumption, which, in turn, leads to an increase in the level of angiogenic factors and the expression of inflammation and ER stress-associated genes [21] . In mice exposed to high-fat diet, sign of hypoxia can be detected after 3 days of diet together with increased protein level of its main mediator, the hypoxia inducible factors (HIF1a), vascular endothelial growth factor expression levels, and accumulation of lactate. The link between hypoxia and the appearance of inflammation in vWAT was demonstrated in both mouse models of both HIF1a genetic deletion and transgenic overexpression establishing its critical role in the inflammatory response and in the onset of insulin [15, 22] .
Altogether, these alterations are responsible at least in part for the subsequent inflammatory response and decreased insulin sensitivity, as discussed below.
Adipose tissue proinflammatory responses induced in obesity: secretion of proinflammatory cytokines and modulation of adipokine secretion
The first evidence showing the implication of adipose tissue in the obesity-related inflammatory response came 20 years ago, when Hotamisligil et al. [23] demonstrated that the production of tumor necrosis factor alpha (TNF-a) was induced in the visceral fat pad of obese rodents and that the neutralization of this cytokine improved their insulin sensitivity. Excessive nutrient consumption triggers an inflammatory process, also called 'metaflammation' [2, 24] , that is initiated and sustained by metabolic cells, which are at the interface between metabolic inputs and the inflammatory outputs. Metaflammation is characterized by being low-grade compared to the acute inflammatory response, and chronic, as cytokine expression and immune cell infiltration appear gradually and remain unresolved over time. WAT is likely the primary site where metaflammation originates, although, to a certain degree, other metabolic tissues, such as liver (as discussed later), pancreas, and gut cells associated with the gut microbiota are also involved, with important consequences for metabolic homeostasis.
Upon nutrient overload, the inflammatory process is likely initiated by the cellular and tissular damages, described above. These alterations lead to two main processes. First, they increase the number of dead adipocytes showing necrotic-like abnormalities [25, 26] . In turn, these necrotic events trigger the recruitment of inflammatory cells that secrete proinflammatory soluble mediators. In parallel, the adipocytes themselves undergo a global and profound change in their secretome profile, with not only an increased release of mediators of the clotting process, such as PAI-1, but also an increased expression and secretion of proinflammatory cytokines [27, 28] and alterations in the level of several adipokines [29] .
As mentioned above, TNF-a was the first identified major proinflammatory cytokine released from the obese adipose tissue, in mice and in humans [30, 31] . It is mainly expressed by monocytes and macrophages that infiltrate the obese adipose tissue, as well as by obese adipocytes [23] and has a central role in many different inflammatory diseases.
The CC-motif Chemokine Ligand 2 (CCL2) also known as Macrophage Chemoattractant Protein 1 (MCP1), is one key chemokine expressed by the adipocytes whose levels positively correlate with the increased adiposity and whose presence is sufficient to induce the recruitment and infiltration of macrophages in the adipose tissue initiating the inflammatory response and obesity-related insulin resistance [32] . Although the work of Kirk et al. reported no differences in adipose tissue inflammation or macrophages accumulation in CCL2-deficient mice [33] , other studies showed that lack of CCL2 or of its receptor CCR2 in the adipose tissue reduces macrophage accumulation and ameliorates the metabolic profile as well as the insulin sensitivity and hepatic steatosis of obese mice [32, 34] .
Interleukin 6 and IL18 are cytokines produced by the adipose tissue and positively correlated with the adiposity level [35, 36] , even in a regimen of weight loss [37, 38] . However, the metabolic consequence of the increase in these two cytokines remains controversial, as discussed later.
The adipokines also play a role in modulating inflammatory responses. Adiponectin has anti-inflammatory properties, via inhibition of TNF-a synthesis in endothelial and hepatic cells and induction of the production of anti-inflammatory cytokines such as IL-10 and IL-1 receptor antagonist (IL-1RA) in macrophages and dendritic cells [39] . Adiponectin reduction observed in obesity limits these anti-inflammatory effects. In contrast, leptin increases circulating levels of proinflammatory mediators released by various cell types, including macrophages. Leptin is an adipokine involved in the regulation of food intake through the central nervous system. Mice lacking leptin (ob/ob mice) are hyperphagic and develop obesity and insulin resistance, which can be reverted by the administration of leptin [40] . Leptin circulating levels are positively associated with the adipose tissue mass, suggesting a possible leptin resistance in obese patients as they do not show the expected anorexic response [40] . The proinflammatory activity of leptin is mainly mediated by its ability to increase the production of TNF-a and IL6 by monocytes, and of CC-chemokine ligands by macrophages [41] [42] [43] . In addition, it increases the production of IL2 and interferon c (IFNc) and suppresses the production of the anti-inflammatory cytokine IL4 in T cells [44] . In the obese adipose tissue, proinflammatory signals such as TNF-a [45], stimulate the production of leptin, which in turn maintains and exacerbates the inflammatory response.
Resistin is another major secreted adipokine whose levels increase with obesity and correlate with both inflammation and insulin resistance in animal models [46] . The proinflammatory action of resistin in human mononuclear cells is mediated by the increase in the expression levels of TNF-a and IL6 in monocytes [46] and of adhesion molecules (VCAM1, ICAM1, and pentraxin 3) in vascular cells that enhance leukocyte adhesion [47] .
Altogether, the obesity-or overnutrition-driven changes in the secretion profiles of these cytokines and adipokines in the vWAT are part of the process that leads to the recruitment of inflammatory/immune cell in this tissue. ). They produce proinflammatory cytokines, such as TNF-a, iNOS, and IL6, which further promote obesity-associated inflammation not only in mice [54] but also in obese patients where the accumulation of macrophages has been shown to correlate with higher circulating levels of TNF-a [55, 56] .
Recruitment of inflammatory and immune cells in the WAT
Another concurrent effect, which contributes to the worsening of obesity-related inflammation, is mediated by paracrine action of leptin on immune cells. Leptin has been reported as a strong mediator of monocytes proliferation, macrophages phagocytosis, cytokine expression, and chemotaxis [57] by stimulating the production of IL2, IL12, and IFNc [58] . Moreover, mast cells in the adipose tissue of obese mice contribute to leptin production, which in turn affects macrophage polarization toward the M1 proinflammatory status. Consistently, mast cells from leptin-deficient mice are able to polarize macrophages toward the less inflammatory M2 phenotype [59] .
Finally, other stimuli in the context of obesity can influence macrophage recruitment and activation, such as fatty acids, fetuin-A, Kr€ uppel-like factor 4 [60] , or cold exposure [61] . Unsaturated fatty acids have been identified as promoters of macrophage activation in obesity through a mechanism mediated by the binding to the pattern recognition receptor Toll-like receptor 4 (TLR4) [62] . Recent observations suggested that FFAs are not direct ligands of TLR4 but bind via fetuin-A, a glycoprotein produced by the liver that may act as a transporter of FFAs in the circulation and as endogenous ligand for TLR4, presenting in this way FFAs to the receptor [63] . All these effects favor not only recruitment of macrophages to the inflated adipose tissue but also their polarization to M1 type. However, some studies have demonstrated a mixed M2/M1 phenotype in the adipose tissue of obese mice and humans [64] [65] [66] , while others depicted a complex scenario where the most abundant 'metabolically activated' (MMe) macrophages have a different phenotype compared to classically activated M1 macrophages, suggesting that their activation is occurring via mechanisms that are different from those occurring during infection [67] .
Currently, an active research field is studying ways to counteract the inflammatory response in WAT by pushing the rise in number and activity of brite (brown-in-white) cells, in order to not only boost the whole-body energy expenditure but also to improve adipose tissue inflammation and thus insulin resistance [68] . Indeed, prolonged cold exposure increases adiponectin secretion that in turn is responsible for the activation and recruitment of anti-inflammatory M2-type macrophages [69] .
After the first wave of newly recruited M1 macrophages, that have the role to clear necrotic adipocytes and remodel the extracellular matrix [26] , and with the persistence of excessive nutrient intake, the activation of the adaptive immune system response is occurring in the adipose tissue. Indeed, activated M1 cells act as antigen presenting cells, via MHC class I and II molecules, thereby initiating the response of the adaptive immune system and amplifying the adipose tissue obesity-driven inflammation (Fig. 1) .
Among the immune cells of the adaptive response, CD4 + T cells are thought to play an important role in the progression of the obesity-related inflammatory response. T helper lymphocytes expressing CD4 can be subdivided into a T H 1 and T H 2 sublineage, based on their secretion profile. T H 1-cells tend to secrete proinflammatory cytokines responsible for the elimination of pathogens and the perpetuation of the inflammatory response. On the other hand, T H 2 cells produce antiinflammatory cytokines including IL4, 5, 10, and 13, which promote antibody synthesis but inhibit several functions of phagocytic cells. Compared to the scWAT of obese mice as well as to vWAT of lean mice, the vWAT of diet-induced obese mice exhibits a higher number of proinflammatory CD4 + T H 1 cells secreting IFNc (Fig. 1 ). This contributes to the creation of a feed-forward loop in the obese vWAT, where the increased production of IFNc by T H 1 cells favors the classical (proinflammatory) activation of macrophages [70] . The importance of another subset of CD4 + T cells, the regulatory CD4 +
Foxp3
+ T reg cells, in the vWAT is highlighted by its relative defection upon inflammatory response of the adipose tissue in obesity. This particular population of WAT T reg seems to be extremely important for metabolic processes and for the regulation of inflammatory response in vWAT. They are present in high number in lean mice (40-80% of CD4 + T cells in vWAT), while they are dramatically reduced down to 30% of the initial population during obesity [71] . However, how this particular new cell compartment contributes to the worsening of the inflammatory response is not yet clarified.
Another immune cell type contributing to the creation of a modified milieu in the AT, are the CD8 + T cells, whose depletion improves insulin sensitivity in diet-induced obese mice. These cells localize in close proximity to M1 cells in the crown-like structures, suggesting a possible cross-talk between CD8
+ and M1 cells. This hypothesis is also supported by the fact that M1 cells that are cocultured with CD8 + cells increase their production of TNF-a [72] (Fig. 1) .
B cells, another class of cells belonging to the adaptive immune system, are also playing a role in the pathogenesis of obesity-related insulin resistance. In mouse model of diet-induced obesity, B cells accumulate in vWAT at early stage (i.e., by 4 weeks), and contribute to the worsening of insulin sensitivity. This mechanism is in part mediated by their effect on CD8 + and T H 1 cells, which are induced to produce proinflammatory cytokines, and in part by their own release of Immunoglobulin G (IgGs). In line with this observation, B-cell depletion using CD20 monoclonal antibody reduced the levels of proinflammatory mediators such as IFNc and TNF-a and ameliorated glucose metabolism [73] .
This already complex scenario has been recently enriched by two reports that highlighted the essential role of natural killer (NK) cells in this process. This specialized subset of lymphocytic cells has normally two functions. First, they can destroy tumor and infected cells using the cytolytic activities of enzymes such as perforin and granzyme. Second, they are able to modulate the activity of many immune cells by secreting many different pro-and anti-inflammatory cytokines, including TNF-a, IFNc, and IL10 [74] (Fig. 1) . Two different groups demonstrated that NK cell number dramatically increase in the vWAT of mice exposed to high-fat diet (HFD) and that these cells have a major role in the recruitment and the M2-M1 macrophage polarization [75, 76] . Wensveen et al. showed how NK cells start to accumulate in the vWAT within few days of high-fat diet, with the maximum number detected at 2 weeks, and this correlates with the upregulated expression of NK Cell-activating Receptor (NCR1) ligand in adipocytes. In turn, NCR1 is thought to activate vWAT-resident NK cells thereby inducing the production of IFNc, a strong modulator of M1 polarization (Fig. 1) . Similar results come from the work of Lee et al., where the authors show how the modified milieu, created by a prolonged high-fat diet (12 weeks), induce in the vWAT the production of proinflammatory cytokines, such as CCL3, CCL4, CXCL10, and IL15, which serve as chemo-attractants for NK cells. NK cells are then responsible for the production of CCL2 and TNF-a, which will promote monocyte recruitment and activation, respectively. Together these works agree on the crucial role of NK cells in the early and late phases of obesity, showing how selective depletion of this particular immune cell population is able to improve metabolic phenotype and insulin resistance of HFD-treated mice.
Local metabolic consequences of vWAT remodeling
Cellular and tissular damages together with the inflammation of the vWAT along obesity development have local metabolic consequences which are interconnected: a decreased insulin sensitivity and a limitation of the capacity of the vWAT to store lipids.
While section Linking metabolism and inflammation is dedicated to insulin signaling and its perturbation upon obesity, we can here mention two specific actions in adipocytes with that respect. First, the remodeling of the cortical actin in adipocytes impacts the insulindependent translocation of the glucose transporteur Glut4 to the membrane. Second, in mice, the enhanced secretion of the adipokine Resistin interferes with the normal insulin signaling by increasing the expression of the Suppressor Of Cytokine Signaling 3 (SOCS3), a known inhibitor of insulin action in adipocytes [77] . Other more systemic mechanisms are likely to operate and are reviewed in the section Metaflammation and specific aspects of PPARs.
One paradoxical consequence of the adipose tissue remodeling and its decreased insulin sensitivity during overnutrition is a limitation of the vWAT to further accumulate lipids. This occurs through several mechanisms. The first one is the fact that adipocytes are less sensitive to the antilipolytic effects of insulin. This results in a sustained lipolysis even in fed state, which augments the efflux of FFAs in the systemic circulation (Fig. 2) . The second fact is that proinflammatory cytokines produced by inflamed WAT, such as IL6 and TNF-a, reduce the activity of lipoprotein lipase (LPL) [78] (Fig. 2) , the enzyme that hydrolyzes TGs contained in very low-density lipoproteins (VLDLs) and chylomicrons at the surface of capillary endothelium [79] . This reduction thus impairs the uptake of FA into the adipose tissue for storage. Consistent with this important role in the regulation of lipid flux, LPL upregulation in the adipose tissue protects against the ectopic accumulations of lipids by increasing the portion of FAs stored in the adipocytes with beneficial effects on obesity-induced insulin resistance [80] . Interestingly, scWAT maintains its ability to correctly store lipids upon HFD feeding, as demonstrated in Interferon Regulatory Factors 5 (IRF5)-deficient mice [81] . Thus, a strategy directed at limiting vWAT expansion to the expenses of the scWAT might be beneficial for the whole-body homeostasis. However, some clinical
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FEBS Letters 591 (2017) 3061-3088 ª 2017 Federation of European Biochemical Societies studies are reporting the observation that vWAT and scWAT have no difference in terms of adipose tissue macrophage (ATM) accumulation in severe obese patients [82] . This controversy may be linked to the fact that in the extreme conditions of obesity even the scWAT looses the capacity to properly store lipids, leading to the accumulation of activated ATM.
Thus, inflammation and insulin resistance are major processes that, in the early phase, take place in the vWAT upon overnutrition and obesity development. The consequences are not only local but results in a systemic low-grade inflammation and increased levels of circulating FFA that will particularly affect the liver.
Diet-induced modifications occurring in the liver
The liver has a central metabolic role. More specifically in the context of this review, the liver regulates metabolic homeostasis across the alternance of fed and fasting states on daily basis, as summarized in Box 2. In context of chronic overnutrition, the liver must cope on the one hand with the direct alteration of these homeostatic metabolic responses. On the other hand, the liver must also cope with metabolites and inflammatory signals coming from the adipose tissue as described above.
NAFLD as a result of the imbalance between uptake and export of lipid in the liver As clarified by the World Gastroenterology Association, NAFLD is a condition defined by excessive fat accumulation in the form of triglycerides (steatosis) in the liver. A subgroup of NAFLD patients displays liver cell injury and inflammation in addition to excessive fat (steatohepatitis), a condition designated as nonalcoholic steatohepatits (NASH).
In obesity, hepatosteatosis represents the first step of NAFLD. Hepatosteatosis correlates quite well with abdominal adiposity and its incidence is showing the same positive trend as obesity. In a simplified manner, hepatosteatosis results from increased fatty acid uptake, decreased fatty acid use, and decreased export in form of VLDL. Adipose tissue-derived FFAs are the major source of hepatic fatty acids and they represent 59% of liver fat in NAFLD patients [83] . The increased fatty acid uptake is sustained by the increased expression of CD36 in the liver and skeletal muscle of obese patients with NAFLD compared to obese subjects with normal intrahepatic TG content [84] . At the same time, the downregulation of CD36 and the enhanced lipolysis that take place in the adipose tissue, further exacerbate the flux of FFAs toward the liver and the skeletal muscle in NAFLD patients (Fig. 2) . The role of FFA uptake in hepatosteatosis was further corroborated in animal model of NAFLD lacking transporters such as CD36 and FATPs, where reduction in liver fatty acid influx prevented steatosis [85, 86] .
The remaining part of hepatic TG stores derives from dietary fatty acids and de novo lipogenesis (DNL) (see Box 2 for DNL in physiological context). The increase in DNL precedes the development of steatosis and is due in part to the insulin resistance of the muscle, which provokes an increased flux of ingested carbohydrates toward the liver [87] . Compared to healthy subjects, in patients with NAFLD the newly synthetized lipids account for a much higher percentage of Fig. 2 . Liver-adipose tissue cross-talk in lean and overnutrition state. A. Lean state. Insulin signaling in the liver induces phosphorylation of the protein kinase AKT. AKT-dependent downregulation of forkhead box (Foxo) transcription factor reduces the transcription of gluconeogenic genes, such as PhosphoEnolPyruvate CarboxyKinase (PEPCK), and hepatic glucose production (HGP). AKT-dependent upregulation of the mammalian target of rapamycin complex (mTORC) upregulates Sterol Regulatory Element-Binding Protein 1c (SREBP1c) thus inducing de novo lipogenesis (DNL) and triglyceride (TG) synthesis. DNL inhibits both the transport of fatty acids in the mitochondria via carnitine palmitoil transferase carrier (CPT) and the b-oxydation (b-ox), which is controlled by peroxisome proliferator-activated receptors a (PPARa). Hepatic TGs are secreted in the circulation in form of very low-density lipoproteins (VLDLs) to reach muscle and adipose tissue where they are taken up, through the action of CD36 and lipopotein lipase (LPL). In adipose tissue, insulin inhibits the release of nonesterified fatty acids (NEFAs). (B) Overnutrition. In obesity, hepatic DNL and HGP are both active. PPARc is upregulated in hepatosteatosis, further inducing DNL and hepatic TG content. Aminoacids (AA) derived from the diet influence mTORC/S6 kinase (S6K) pathway that, through an intertissue connection, affects LPL activity in the adipose tissue and thus increases circulating TGs. Hepatic VLDL secretion increases, but their uptake by adipose tissue is reduced because of the low expression of CD36 and LPL. Conversely, CD36 and LPL are more expressed in muscles and liver that therefore internalize more VLDLs. HGP upregulation is due to different processes: (a) lower utilization of glucose due to reduced glucokinase (GCK) activity, (b) increased adipose tissue lipolysis due to insulin resistance and consequent increase in the releasing of NEFAs in the circulation. Hepatic acetyl-CoA content and pyruvate carboxylase (PC) activity increase, with consequent higher transformation of pyruvate into glucose. In obesity, both liver and adipose tissue undergo an inflammatory response with production of proinflammatory cytokines: interleukin 6 (IL6), tumor necrosis factor alpha (TNF-a), C-reactive protein (CRP), plasminogen activator inhibitor 1 (PAI-1).
the total intrahepatic fatty acids (15-23% vs 5%) [88] . Highly lipogenic hepatocytes undergo a phenotypic change characterized by enhanced expression of adipogenic genes such as Sterol Regulatory Element-Binding Proteins (SREBPs), Adipose DifferentiationRelated Protein (ADRP), and PPARc [89, 90] .
At the same time, oxidation of fatty acids in the liver is reduced, contributing to their consequent accumulation in the liver. More particularly, the expression of the nuclear receptor PPARa [91] is blunted, resulting in a reduction of fatty acid transport to the mitochondria, via reduction of Carnitine Palmitoyl Transferase 1 (CPT1) expression, and decreased fatty acid b-oxidation. Reciprocally, liver-specific deletion of PPARa also caused the development of hepatic steatosis in aging in mice fed a standard diet [92] . Finally, the TG outflow rate through VLDL contributes to the maintenance of hepatosteatosis. Although subjects with NAFLD have greater VLDL secretion than those with normal intrahepatic TG content, this secretion does not increase linearly with the increasing TG amount but rather reaches a plateau. Therefore, the increase in VLDL secretion rate, in NAFLD patients, is not able to compensate for the increased rate of TG accumulation [93] .
Hepatosteatosis per se is not necessarily deleterious, and may remain clinically silent, that is, the metabolic functions of the liver are unaffected by the 'simple' accumulation of lipids. However, in a number of cases, which in humans reach one-third [94] of the NAFLD patients, complications can ultimately lead to NASH, Box 2. The healthy liver
Anatomy and cellular composition
The liver is a central metabolic organ, which receives blood from:
• The gastrointestinal tract and the spleen via the hepatic portal circulation. This blood is rich in nutrients coming from the absorbed food. The first passage through the liver of potentially toxic substances allows their detoxification prior to reaching the systemic circulation,
• The hepatic artery, which delivers oxygen to the cells
The drained blood coming from both the portal vein and the hepatic artery join the general circulation via the inferior vena cava. Eighty percent of the liver volume is occupied by hepatocytes, the parenchymal cells that perform the majority of hepatic metabolic activities. Nonparenchymal cells consist of Kupffer cells (specialized macrophages), endothelial cells, and also NK, NKT, and CD4+ T immune cells [233] , which together play an important role in the hepatic immune response [234] . Stellate cells, which store vitamin A, are mainly quiescent in the healthy liver, and are rather characterized by their profibrotic activity in the damaged liver.
The healthy liver in feeding condition
The high levels of glucose reaching the liver in postprandial state first drive its condensation into glycogen to reconstitute the glycogen store. The excess of glucose is used for de novo lipogenesis (DNL), in which pyruvate coming from glycolysis enters a process leading to palmitate via acetyl-CoA and malonyl CoA [235] . The fatty acids generated by DNL, together with dietary fatty acids are converted in triglycerides and released in the bloodstream in the form of very low-density lipoproteins (VLDLs). Dietary amino acids can be used by the liver as a source of energy, or to generate proteins and glucose.
The healthy liver in fasting condition Glycaemia levels are maintained through glycogenolysis and then through hepatic glucose production by gluconeogenesis. The white adipose tissue releases FFAs in the bloodstream as lipolysis products, which are internalized in the liver via specific transporters. Hepatic fatty acid oxidation produces ketone bodies, which will fuel extrahepatic tissues particularly upon prolonged fasting. The nuclear receptor PPARa is a lipid sensor and a key regulator of mitochondrial b-oxidation, peroxisomal b-oxidation, and other aspects of fatty acid metabolism [236, 237] , in the liver during fasting.
where inflammation and fibrosis are severely altering liver functions.
From NAFLD to NASH: the role of inflammation in the liver in obesity and overnutrition
A prolonged overnutrition condition triggers in some case the progression of NAFLD from the simple hepatosteatosis to the development of inflammation, fibrosis, and NASH [95] . A 'multihit' hypothesis is presently widely accepted to explain this evolution. As described above, liver lipid accumulation and insulin resistance (see also Metaflammation and specific aspects of PPARs) appears early in NAFLD and worsens steatosis as a result of increased DNL. These alterations expose the liver to 'multihits', which include mitochondrial dysfunction, oxidative damage, altered hepatocyte apoptosis, increased levels of fibrogenic and proinflammatory mediators and activation of stellate and Kupffer cells [91] . We will focus below on the inflammatory process, which is a main contributor to the worsening of the liver status.
The inflammatory response of the liver parallels the increase in hepatic lipid accumulation and the development of obesity. Hepatic inflammatory mediators include C-reactive protein, PAI-1, fibrinogen, and IL-6, which mark the presence of a 'subacute inflammation' in the liver [96] . However, as for the adipose tissue, the immune cells are the major contributors of liver inflammation.
Two different populations of macrophages mainly drive the inflammatory response in liver: the resident macrophages, known as Kupffer cells, and the recruited macrophages, which migrate into the liver during obesity [97] . Kupffer cells derive from embryonic progenitors of the yolk sac and are found in the liver sinusoids in close proximity with sinusoidal endothelial cells [98] , where they protect against pathogenic compounds. However, their activation, induced by toxic lipid droplets present in the liver, seems to represent the 'first hit' of NAFLD/NASH pathogenesis [99] . Activated Kupffer cells further enhance hepatic inflammation via the secretion of monocyte chemoattractant CCL2 [100] , which triggers the recruitment and activation of monocytes from the bloodstream. These monocytes are able to infiltrate the liver as a result of liver injury and to differentiate into proinflammatory M1 macrophages [101] . The primary role of Kupffer cells is supported by the fact that their depletion, using clodronate injections, results in improved liver steatosis, and insulin resistance [102] .
However, liver inflammation is also sustained by other immune cells that entertain complex cross-regulation and activation with Kuppfer cells and macrophages [103] . Dendritic cells are antigen-presenting cells that participate to the innate immune defense in the liver and provide support to macrophages. NK cells are the major lymphocyte population in the liver, representing 30-50% of total lymphocytes [104] . NKs as well as T cells are not contributing to the steadystate condition of the liver but are extremely important during the inflammatory response. Activated Kupffer cells are responsible for the stimulation of these cells through a signaling pathway initiated by TLRs. TLR2 or 3 induce Kupffer cell secretion of IL18 and IL1b, thus activating NK cells [105] , while TLR4 is responsible for the upregulation of adhesion molecules such as ICAM1 and VCAM on Kupffer cells and hepatic stellate cells, which are then mediating T-cell trapping and activation [106] . In addition, neutrophils are polymorphonuclear leukocytes important in sustaining the liver inflammation process. Hepatic infiltration of neutrophils is an acute response to liver injury, hepatic stress, or systemic inflammatory signals [107] that aggravates the inflammatory reaction by the secretion of cytotoxic reactive oxygen and nitrogen species or of proinflammatory cytokines such as IL1b and TNF [108] . Neutrophil dysfunction is also associated with the development of liver fibrosis and cirrhosis in NASH. Indeed, the neutrophil-to-lymphocyte ratio is higher in patients with NASH and advanced fibrosis, and has been proposed as a noninvasive marker to predict advanced liver disease [109] .
Chronic liver inflammation is also associated with tissue damage and remodeling as well as fibrosis [110] . Hepatic macrophages are able to induce differentiation of hepatic stellate cells, the primary cells involved in liver fibrosis, into myofibroblasts and to promote their survival with the secretion of TNF and IL1 [111] . The establishment of a modified microenvironment, where inflammation and fibrosis coexist enhancing liver injury, is thought to be at the base of the progression of liver steatosis to NASH.
The adipose tissue-liver cross-talk in metaflammation
As described above, there are two main processes that start in the adipose tissue and have an impact on the liver environment: the development of systemic lowgrade inflammation in obesity, and the increased afflux of FFAs to the liver due to increased lipolysis, together with the inhibition of LPL activity. The importance of WAT lipolysis was also recently highlighted by the efficiency of the pharmacological inhibition of the adipose triglyceride lipase in decreasing insulin resistance and hepatosteatosis in mice [112] .
In addition to this metabolic regulation, adipose tissue-derived adipokines and pro-inflammatory cytokines can directly act on liver metabolism and the development of NAFLD [113] . Adiponectin, for example, has a protective role in the progression of hepatic steatosis to fibrosis and NASH. In the model of dietinduced obesity in rats, adiponectin overexpression stimulates hepatic b-oxidation and protects the liver from steatosis and inflammation, thus improving insulin sensitivity [114] . Indeed, adiponectin inhibits hepatic DNL and gluconeogenesis by reducing the expression of the lipogenic transcription factor SREBP1-c and the rate-limiting enzyme Phosphoenolpyruvate Carboxy Kinase (PEPCK), respectively [115] . In addition, adiponectin improves glucose utilization by activating an adenosine monophosphateactivated protein kinase (AMPK-dependent pathway) [116] . In agreement with mouse studies, adiponectin levels are reduced in patients with NAFLD [117] and negatively correlate with liver alanine aminotransferase (ALT) and c-glutamyltranspeptidase [118] , which are indicators of liver lesions.
Leptin, on the other hand, negatively influences the onset and the progression of NAFLD, being positively correlated with serum level of ALT in humans [119] . Moreover, it acts as profibrogenic mediator by stimulating the production of a-smooth muscle actin (a-SMA), collagen 1 and the tissue inhibitor of metalloproteinase 1 (TIMP1) in human stellate cells [120] . However, it has been shown that leptin produced by the adipose tissue has an insulin sensitizer effect in the liver and skeletal muscle with regularization of pancreatic b-cell activity [121] . TNF-a and IL-6 also correlated with the progression of NAFLD to NASH and with the onset of insulin resistance by increasing the production of SOCS3 in the liver [122] .
Finally, the adipose tissue-derived FFAs may directly act as signaling molecules in the liver via interacting with the transcription factor PPARa, triggering the expression of its target genes and more particularly fibroblast growth factor 21 (FGF21) [123, 124] . In turn, FGF21 is part of the reciprocal cross-talk from the liver to the adipose tissue. It is produced mainly by the liver in the fasted state, and has a direct effect on adipose tissue, stimulating both lipolysis and the expression of adiponectin [125] . This signaling to adipose tissue is required for FGF21 activity on increasing insulin sensitivity. However, it also has adipose tissue-independent activity, more particularly on increasing energy expenditure [126] . It is considered as a good candidate for the treatment of T2D and metabolic syndrome primarily for its ability to reduce plasma TGs in rodents and humans [127, 128] . FGF21 would act via reducing VLDL secretion in the liver and redirecting TG-rich lipoproteins toward WAT, via increased activity of CD36 and LPL in this tissue [129] . Other hepatokines might be discovered, since systematic analyses of the secretome of steatotic hepatocytes identified 32 hepatokines differentially secreted by steatotic vs nonsteatotic hepatocytes. Among them, Fetuin B is increased in patients with hepatosteatosis, and its silencing in mice improved glucose tolerance [130] .
Linking metabolism and inflammation: insulin sensitivity as the central piece
With the onset of T2D, obese patients display an array of metabolic alterations including hyperinsulinemia, hyperglycemia, and hypertriglyceridemia. High levels of insulin are not able to lower the glycemia: thus the name of insulin resistance. This insulin signaling has been at best studied in the liver, but resistance appears in all metabolic tissues, particularly the adipose tissue, which will be discussed herein in light of their links to metaflammation.
Insulin signaling in the liver and pathways to insulin resistance in the context of obesity
Insulin signaling has been extensively studied. An overview of insulin signaling in the liver, with a focus on the elements relevant for this review is shown in Figure 3 .
Briefly, in terms of processes, the peak of insulin in the postprandial period drives both a reduction in hepatic glucose production (HGP), and an increase in the rate of lipid production via DNL. In insulin-resistant liver, the insulin-dependent activation in DNL is maintained, but there is a failure in decreasing glucose production, a process known as 'selective hepatic insulin resistance' [131] (Fig. 2) .
In this context, the observation by Lu et al. that mice lacking Akt1, Akt2, and forkhead box transcription factor 1 (Foxo1) do not show any defect in insulin-mediated suppression of gluconeogenesis [132] , raised the question whether other mediators could have a role in the postprandial reduction of HGP mediated by insulin [133] . The idea that an intertissue connection could participate in regulating this metabolic process comes from the observation that the insulin-dependent suppression of HGP is occurring even in mice with liver specific ablation of insulin receptor [134] . Subsequently, Perry et al. [135] demonstrated that HGP is highly sensitive to hepatic acetylCoA, whose concentration depends on the levels of circulating FFAs. When insulin fails to suppress lipolysis in adipose tissue, the high FFA flux to the liver determines a rise in the levels of hepatic acetylCoA, which, in turn, maintain high the pyruvate carboxylase activity and the conversion of pyruvate into glucose (Fig. 2) . The critical role of FFAs in the regulation of HGP in obesity-related insulin resistance was also pointed by Titchenell et al. [136] . These authors suggested that, in fact, insulin action in the liver directly controls only hepatic lipogenesis, while HGP is regulated by insulin in an indirect way through the modulation of the levels of circulating FFAs. Both these reports thus highlighted the key role of FFAs as mediators of the tight connection between liver and adipose tissue in the regulation of HGP in insulin-resistant mice. It must be noted, however, that recent studies highlighted some contexts in which hepatic lipid production is necessary and even beneficial. More particularly, the accumulation of monounsaturated fatty acids such as oleate rather than polyunsaturated fatty acids, seems rather protective against insulin resistance and glucose intolerance [123, 137] .
Finally, an additional level of complexity comes from the role of amino acids, which in obesity can activate the Mammalian Target Of Rapamycin Complex 1/S6 Kinase (mTORC1/S6K) signaling pathway [138] . This signal then activates an intertissue neuronal pathway acting on the adipose tissue that results in a reduction of LPL activity and consequent elevation in serum TGs [139] .
Molecular pathways that link inflammation and insulin resistance
The link between inflammation and the onset of insulin resistance in obese patients remained obscure until the hypoglycemic effects of salicylates were reinvestigated, leading to the identification of the Inhibitor of Nuclear Factor jB (IjB) kinase b (IKKb)/NFkB axis as their molecular target [140] . Concomitantly, increased adiposity and dysregulation of lipid metabolism were shown to correlate with the activation of a diverse range of stress-responsive pathways including the Jun N-terminal Kinases (JNKs), IKKb, and inflammasome, which are important mediators of the inflammatory response.
Jun N-terminal Kinases are members of the Mitogen-Activated Protein Kinases (MAPK) family, which are induced in response to cellular stress signals [141] and are able to phosphorylate and activate the protein cJun, a member of the Activator Protein-1 (AP-1) transcription factor family. Their role in the induction of insulin resistance has been largely studied in the past and several mechanisms are proposed to explain how JNKs can induce insulin resistance in response to excess of adiposity. First, JNKs are responsible for the phosphorylation of Irs1 in serine-307, inhibiting the interaction of Irs1 with the insulin receptor [142] , whose signaling is normally occurring through the counter-regulatory serine/threonine phosphorylation. Second, JNK1 and 2 are proposed as key mediators in macrophages to allow their recruitment and activation in the obese vWAT. Mice lacking JNK1/2 specifically in myeloid cells are largely protected from the inflammation associated with diet-induced obesity, with less severe insulin resistance, decreased accumulation of macrophages and a relative lower expression of M1-specific cytokines [143] . Finally, JNKs have a role in the reduction of FA oxidation and in the onset of steatosis and insulin resistance in the liver, mainly acting as a negative regulator of PPARa activity and FGF21 expression in hepatocytes, via the activation of the Nuclear Receptor Co-Repressor (NCoR1) complex [144] .
The IKKb is another inflammatory kinase playing a critical role in the onset of insulin resistance. Its activity is highly selective toward its physiological substrates, the IjB protein inhibitors of NFkB. Phosphorylation by IKKb directs IkBa to proteasomal degradation, thus allowing the release of NFkB, a master transcriptional regulator of inflammation. Once delivered from its complex with IkBa, NFkB translocates into the nucleus, where it affects the expression of numerous target genes involved in insulin resistance [145, 146] . It has been shown that NFkB is activated in the liver of mice fed a high-fat diet, whereas a reduction in its activity or an increased expression of IKKb significantly improve glucose and lipid metabolism [145, 147] .
As described above, IRS1, the first transducer of insulin signaling, can be phosphorylated by JNKs (Fig. 3) . Besides this regulation, IRS1 is also the target of other kinases such as RNA-activated Protein Kinase (PKR), Extracellular signal-Regulated Kinase (ERK), Protein Kinase Ch (PKCh), mTOR, and SOCS, whose activity is influenced by the inflammatory status. Thus, insulin signaling is sensitive to the antagonizing effects of multiple mediators belonging to different cellular pathways related to the inflammatory response. Further highlighting this interference, inflammatory kinases also counteract insulin sensitivity by directly activating transcription factors such as the AP-1, NFjB and interferon regulatory factors (IRFs) and thus modulating the expression of genes important not only in inflammation but also in glucose, cholesterol metabolism and fatty acid synthesis [148] , as detailed below.
Many of the proinflammatory cytokines and adipokines that are produced in obese vWAT, including TNF-a, IL6, IL1b, and resistin, were shown to modulate the activation of the stress-response kinase JNK and IKKb. Therefore, a feed-forward loop arises in obesity, where increased adiposity induces the production of proinflammatory cytokines, which, in turn, activate cellular signaling pathways leading to the onset of insulin resistance.
Tumor necrosis factor alpha was the first adipose tissue-secreted cytokine directly linking inflammation and insulin resistance [23] . It exerts its action on the adipose tissue by enhancing adipocyte lipolysis and increasing Irs1 serine phosphorylation through a mechanism dependent on the activation of JNK1/2 in visceral adipose tissue [149] . TNF-a levels are increased in the adipose tissue and in the plasma of obese individuals [30] , where it correlates with markers of insulin resistance [31] . Moreover, mouse models of genetic loss-of-function for TNF-a, TNF Receptors 1/2, JNKs, are all protected when challenged with high-fat diet [150, 151] . However, the use of TNF-a as target to treat insulin resistance in diabetic patients did not turn to be successful. Clinical trials using short-and longterm administration of TNF-a antagonists were able to reduce systemic inflammatory markers but showed poor effects on insulin resistance [152] [153] [154] .
Interleukin 6 is a proinflammatory cytokine produced mainly by the adipose tissue that is thought to play a role in the onset of insulin resistance. This action would be mediated by IL6-induced reduction in GLUT4 and Irs1 expression levels through the activation of the JACK-STAT signaling pathway and the increased expression of SOCS3 [155] . However, the direct link between IL6 and obesity-induced insulin resistance is controversial. On the one hand, it is thought to suppress insulin ability to modulate gluconeogenesis in liver and this was demonstrated both in mice [156] and in vitro, using HepG2 human cell line [157] . On the other hand, IL6 deficiency worsens hepatic insulin resistance and inflammation in a mouse model of diet-induced obesity [158] . These contradictory results on IL6 role in insulin resistance can be in part explained by its multiple action in different organs (i.e., skeletal muscle or liver) and in part by its different sources (i.e., muscle and adipose tissue).
The action of IL18 is also debated in the literature with negative effects on insulin sensitivity reported in a rat model of metabolic syndrome [159] , whereas IL18-deficient mice show hyperphagia, obesity, and insulin resistance [160] .
Finally, the adipokine resistin was initially reported as a major player in insulin resistance, thus its name. Mice lacking resistin are protected from diet-induced hyperglycemia, due to AMPK increased activity and reduced expression of gluconeogenic genes [161] . However, in humans, the role of resistin is less clear and quite debated, with reports showing a positive association between resistin levels and the development of obesity, insulin resistance and T2D [162] and others refuting any kind of association with the development of metabolic syndrome [163, 164] . One of the possible explanations of the difference between mice and human is the different pattern of resistin expression, which, in mice, is totally restricted to adipocytes, whereas in humans is exclusively observed in macrophages and monocytes [165, 166] .
Lipid mediators of insulin resistance
The altered lipid flux that prevails in obesity has been associated to insulin-resistant states, being both the cause and the result of insulin resistance. Circulating fatty acids can impair insulin signaling mainly in two ways.
On the one hand fatty acids can interfere with the downstream pathways of insulin binding [167] , via the interaction of long saturated fatty acids, such as palmitate, with the receptors TLR2, TLR4 and Nucleotidebinding oligomerization domain, Leucine-rich Repeat (NLR) and Pyrin domain containing 3 (NLRP3) [168, 169] . Upon ligand binding, TLRs trigger a signaling cascade that leads to the activation of IKKb and MAPKs such as p38, JNK, and ERK1/2. In parallel, NLRP3 can be activated by host-derived molecules, including excess ATP, glucose, ceramides, reactive oxygen species, that are abundant in obese individuals.
NLRP3 activation initiates the assembly of the inflammasome, a large multiprotein complex which governs the maturation of the proinflammatory cytokines IL1b and IL-18 [170] [171] [172] . The key role of this complex in the obesity-induced adipose tissue inflammatory response has been demonstrated by the blunted response to ceramide of macrophages derived from the adipose tissue of Nlrp3 knockout mice, which display a reduction in macrophage M1 polarization in the fat tissue [172] .
All these multiple pathways activated by overnutrition converge onto the stimulation of the major inflammatory kinases JNK and IKKb, which, as described above, interfere with insulin signal transduction.
On the other hand, the accumulation of intracellular lipid products, such as diacylglycerols (DAG) and ceramides can directly be the cause of insulin resistance. This last mechanism raises the concept of lipotoxicity, as referred to the ability of excessive lipids to contribute to the pathophysiology of metabolic syndrome and T2D [173] . Once entered in the cell, fatty acids are rapidly esterified with coenzyme A to form acyl-CoAs. These intermediates are then transferred to a glycerol backbone to form mono-, di-, and triacylglycerols. In the liver, the link between DAG accumulation and insulin resistance is attributed to the activation of Protein Kinase Ce (PKCe) [174] , which binds and inhibits insulin receptor kinase activity. By knocking down the hepatic PKCe expression using specific antisense oligonucleotides, Samuel et al. were able to protect rats from lipid-induced hepatic insulin resistance, independently of the increased hepatic lipid levels [175] .
Ceramides represent another class of fatty acid derivatives whose intracellular levels are strongly associated with insulin resistance [176, 177] . Their biosynthesis occurs through the condensation of saturated fatty acids (preferentially palmitate) with amino acids (preferentially serine) to form 3-ketosphingamine, the scaffold for all sphingolipids. The sphingoid backbone subsequently acquires additional fatty acids leading to the production of a series of sphingolipids that include ceramides and other more complex products [178] . Inhibition of ceramide production through the administration of myriocin, a potent inhibitor of Serine Palmitoyl Transferase (SPTLC), prevents the development of insulin resistance and diabetes in obese mice [179, 180] . This insulin sensitizing effect is mediated by a reduction in the circulating levels of leptin and a concomitant increase in adiponectin and FGF21. A decrease in ceramide production was also observed in mice carrying an intestinal-specific Farnesoid X Receptor (Fxr) gene deletion and resulted in a downregulation of hepatic SREBP1c and decreased DNL [181] . Furthermore, supporting the beneficial effect of the hampering of ceramide production, myriocin administration, as well as Sptlc2 ablation specifically in adipose tissue, induces macrophage M2 polarization, most prominently in the scWAT, with concomitant increase in serum anti-inflammatory cytokine IL10 and reduction in proinflammatory cythokines IL6, MCP1, and TNF-a [182] . Conversely, elevated intracellular ceramide levels have been shown to stimulate the ability of phosphatase 2A to dephosphorylate AKT, thus interfering with insulin signaling [177] . Notably, both saturated fatty acids and TNF-a induce SPTLC expression, and the subsequent production of ceramide, via activation of TLR4 [176, 183] and their action is mediated by IKKb. In the case of the TNFa-mediated cascade, this is an emblematic example of how an inflammatory stimulus can promote the production of lipid intermediates, which, in turn, impairs insulin action.
Lastly, a compelling body of evidence has accumulated in recent years showing how intracellular fluctuations of several metabolites, as a function of the metabolic status, may influence the activity of chromatin regulators. The resulting epigenetic changes at the level of DNA and histone modifications have a major influence on the control of gene transcription during embryonic development as well as in the differentiated tissues of the adult organism.
Example of metabolites influencing chromatin-modifying enzymes include acetyl-CoA, which is the universal donor for acetylation reactions [184] , and Sadenosylmethionine, which acts as a methyl donor substrate stimulating DNA methyltransferase reactions [185] . The cross-talk between metabolites and epigenetic regulation is described elsewhere [186] .
Metaflammation and specific aspects of PPARs
Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that function as ligand-activated transcriptional regulators, with both activation and repression mechanisms, depending on the condition/ target. Three PPAR isoforms exist, PPARa, PPARb/d, and PPARc, which are characterized by distinct functions and expression patterns ( Table 1) . Their peculiar role in the regulation of glucose and lipid metabolism and inflammation puts PPARs at the crossroad of many molecular pathways involved in metaflammation development. This paragraph will mainly consider PPAR activity in the adipose tissue and the liver, the tissue focus of this review, and their potential use as therapeutic target for the treatment of obesity [187, 188] .
The PPARa has a crucial role in regulating hepatic fatty acid catabolism and clearance, as demonstrated by its target genes such as CPT1, Carnitine Acycarnitine Translocase (SLC25A20), Medium-chain AcylCoA Dehydrogenase, Acyl-COA Oxidase 1, that globally induce fatty acid oxidation [189] . In addition, PPARa enhances the expression of the FGF21, a secreted factor that further stimulates hepatic fatty acid utilization, but that also improves systemic insulin sensitivity through its extrahepatic enhancement of glucose transporter 1 expression [127, 190] . PPARa Table 1 . Peroxisome proliferator-activated receptors (PPARs). PPARs are ligand-activated transcription factors that bind, in form of heterodimers with the Retinoid-X-receptor (RXR), to specific DNA sequences called PPAR-Responsive Elements (PPRE), at the regulatory regions of target genes [238] . The three PPAR isoforms, PPARa, PPARb/d, and PPARc, are encoded in separate genes and share a high structural homology, except for their ligand-binding domain. displays also anti-inflammatory activity, by interfering with NFjB activation [191] . Altogether, these features make PPARa an interesting therapeutic target for obesity, particularly in the presence of hepatosteatosis. Selective PPARa-agonists, such as fibrates were efficiently used for decades in hyperlipidemic patients to lower plasma triglycerides [192] . However, and despite encouraging results obtained in mouse models of NAFLD, these molecules did not prove advantageous in the treatment of NAFLD/NASH in humans, likely due to their lower potency in humans, compared to mice [193] (reviewed in Ref. [193] ). Furthermore, a number of side effects (i.e., increased risk of acute kidney injury, rhabdomyolsysis, and gallstone formation) were associated with their long-lasting use [194] .
Another key positive modulator of FA oxidation, particularly in skeletal muscle, is PPARb/d. However, in the liver, FA oxidation is mainly under the control of PPARa, while PPARb/d-selective activation suppresses hepatic gluconeogenesis, enhances carbohydrate catabolism [195] , and has anti-inflammatory effects in the liver by dampening Kupffer cell activation [196] . In the adipose tissue, PPARb/d inhibits FFA release. While the selective PPARb/d ligand GW501516 was discontinued from clinical trials for favoring tumor development in several organs, KD3010 [197] is currently in phase III clinical trial for the treatment of obesity, NASH, and T2D. A detailed description of other PPARb/d agonist can be found elsewhere [198] .
In the adipose tissue, PPARc is the master regulator of adipogenesis [199] and its activation with Thiazolidinediones (TZDs) leads to de novo differentiation of adipocytes. TZDs are potent insulin sensitizer agents, but their clinical use in the last years has been strongly limited due to the associated risk of increased body weight, bone fractures, congestive heart failure, and bladder cancer [200, 201] . In humans, PPARc activation triggers apoptosis of large fat cells in vWAT and scWAT and induces differentiation of preadipocytes only in scWAT [202] , thus favoring scWAT adiposity [203] . The formation of new adipocytes with the activation of genes such as Fatty Acids-Binding Protein 4 (FABP4), CD36, LPL Fatty Acids Transporter (FATP1), and SREBP1 [204] , improves the uptake and storage of plasmatic FFAs in AT, with the subsequent reduction in circulating TGs and of lipotoxic accumulation in nonstorage specialized tissues, such as liver and muscles [205] . TZDs also enhance FFA mobilization upon fasting and ameliorate the postprandial suppression of FFA release triggered by insulin [206] . Interestingly, chronic treatment of human adipocytes with TZDs initiates a 'browning program' characterized by induction of Uncoupling Protein 1 (Ucp1) [207, 208] and of several components of the mitochondrial transport chain [209] , thus initiating a tissue remodeling program that is considered as a promising way to combat obesity through consumption of lipids to produce heat.
Besides their effects on adipogenesis, PPARc agonists also promote the expression of components of the insulin signaling pathway, including the IRS2 and CAP [210, 211] , that contributes to enhance adipocyte insulin sensitivity. In addition, PPARc activation restores the expression and secretion levels of different adipokines such as adiponectin, resistin [212] , IL6, TNF-a [213] , PAI-1, MCP1, and angiotensinogen [214] that are altered in obesity. Thus, TZDs display also beneficial effects on the development of adipose tissue inflammation upon chronic overnutrition. Importantly, such antiinflammatory properties of PPARc agonists are the result of their action not only in adipocytes but also in all the PPARc-expressing immune cells residing in adipose tissue. In macrophages, PPARc acts as negative regulator of classical proinflammatory M1 polarization [215] and promotes the shift toward the alternative M2 macrophage activation in response to IL4 [216] , thus reducing the expression of inflammatory markers such as Metallopeptidase Domain-8 (ADAM8), Macrophage Inflammatory Protein 1a (MIP-1a), Macrophage Antigen 1 (MAC-1), F4/80, and CD68 [217] . In M2 macrophages PPARc is required to induce b-oxidation and mitochondrial biogenesis [218] as well as expression of Arginase 1 (Arg1), a specific M2 marker. In obesity, PPARc has been proposed to play a crucial anti-inflammatory role in the so-called metabolically activated macrophages in the adipose tissue [67] . Consistently, mice lacking PPARc in myeloid cells when challenged with a high-fat diet are more prone to develop obesity and insulin resistance, mainly due to mitochondrial dysfunction and altered glucose disposal in adipose tissue [218, 219] .
More recently, PPARc has been shown to play a role also in regulating the accumulation of T reg cells in vWAT. T reg -specific PPARc ablation reduces the population of vWAT T reg cells on normal chow diet, while injection of PPARc agonist into HFD-treated mice specifically induces an expansion of T reg population in adipose tissue [220] , with beneficial consequences on the tissue inflammatory pattern.
One special note must be made about hepatic PPARc activity in obesity. PPARc, whose hepatic expression is very low in lean subjects, is strongly upregulated in steatotic liver. As a consequence, TZD treatment in obese/NAFLD patients favors the transcription of the lipogenic transcription factors SREBP1c in the liver, thus increasing the hepatic production of TGs and the maintenance of steatosis [221] .
This explains why, in spite of their ability to reduce lipotoxicity by favoring lipid storage in adipose tissue, TZDs are not able to counteract the development of NAFLD in mice exposed to high-fat diet.
In conclusion, although the long-lasting use of PPAR agonists highlighted the occurrence of considerable side effects that raise the necessity to improve their long-term safety profile, the modulation of PPAR activity is still an attractive possibility to ameliorate obesity-related inflammation, insulin resistance, and NAFLD. The development of safer PPAR agonists still requires a deeper understanding of PPAR signaling and their changes in obesity. As an example, in the obese state, PPARc was recently shown to undergo phosphorylation at serine 273, a post-transcriptional modification that alters the transcriptional effects of PPARc and its sensitivity to ligands [222, 223] . The new synthetic compound SR1664, which was shown to block this phosphorylation of serine 273, has been recently proposed as an antidiabetic drug [224] . Another appealing approach that has been explored in the pharmacological use of PPAR agonists is the combination of the therapeutic benefits of the activation at least two PPAR isoforms with the development of dual PPAR agonists. Although so far most of these molecules displayed safety issues, saroglitazar, a dual PPARa/c activator, has currently been approved in India for the treatment of diabetic patients with NAFLD [225] . Finally, a more systematic consideration of species-related differences, when comparing the activity of PPAR agonists in mice and humans, would be also beneficial for the successful development of new therapeutic ligands [226] . The systematic and complementary use of system biology approaches, evaluating PPAR activity in a given tissue/cell, but integrating such information in the context of the whole organism, will perhaps allow accounting for PPAR agonist pleiotropic effects without considering only a single receptor-dependent pathway.
Conclusions and perspectives
Obesity, especially visceral adipose tissue overload, is associated with many metabolic disturbances, and more particularly insulin resistance, dyslipidemia, and NAFLD. In the last years enormous efforts have been made to uncover new mechanisms contributing to the onset of insulin resistance. Particular progresses were made in understanding how nutritional overload, as well as particular classes of metabolites and lipids can induce a plethora of pathological modifications in different metabolic organs that can alter their physiological activity.
The low-grade inflammatory response or metaflammation is a well-established consequence of the dietinduced obesity and the characterization of the mechanism of recruitment and activation of different immune cell population is a very active research field. However, the attempt to study the modulation of the immune response playing with the balance between pro-and anti-inflammatory cells has been pursued mainly in mouse model whose immune system is, for some aspects, different from humans, leaving an open question on the feasibility of a treatment based on a delicate equilibrium that should favor metabolic outcome without causing other perturbations.
The hope to develop efficient cure to improve insulin resistance in obesity using unique target, such as PPARs (but also, for example, AKT or JNK pathways) faded away over the last years. The evidence that the model in which one factor is the primary responsible for the onset of insulin resistance is clearly too simplistic, as is the idea that targeting one single factor will correct the myriad of defects observed in the context of obesity and insulin resistance. Considering the fact that obesity is a disease where multiple organs, endocrine pathways, and inflammatory responses are involved, the future challenge will be to develop a holistic approach where knowledge of different systems are processed together in order to see how they are interconnected in humans. This is the ambitious goal of system medicine, and only its achievement will open the door for personalized medicine.
